Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

被引：0

作者：

Prager, Gerald W. ^{[1
]}

Taieb, Julien ^{[2
]}

Fakih, Marwan ^{[3
]}

Ciardiello, Fortunato ^{[4
]}

Cutsem, Eric Van ^{[5
,6
]}

Elez, Elena ^{[7
,8
]}

Wyrwicz, Lucjan ^{[9
]}

Stroyakovskiy, Daniil ^{[10
]}

Liposits, Gabor ^{[11
]}

Bondarenko, Igor ^{[12
]}

Modest, Dominik P. ^{[13
]}

Amellal, Nadia ^{[14
]}

Tabernero, Josep ^{[7
,8
]}

机构：

[1] Med Univ Vienna, Comprehens Canc Ctr, Dept Med 1, Vienna, Austria

[2] Univ Paris Cite, Georges Pompidou European Hosp, Dept Gastroenterol & Digest Oncol, SIRIC Canc Res Personalized Med, Paris, France

[3] City Hope Comprehens Canc Ctr, Duarte, CA USA

[4] Univ Campania Luigi Vanvitelli, Dipartimento Med Precis, Naples, Italy

[5] Univ Hosp Gasthuisberg, Dept Digest Oncol, Leuven, Belgium

[6] Katholieke Univ Leuven, Leuven, Belgium

[7] Vall dHebron Hosp Campus, Dept Med Oncol, Barcelona, Spain

[8] Int Oncol Bur Quiron, Inst Oncol, Barcelona, Spain

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Oncol & Radiotherapy, Warsaw, Poland

[10] Moscow City Oncol Hosp, Moscow Healthcare Dept, Moscow, Russia

[11] Reg Hosp West Jutland, Dept Oncol, Herning, Denmark

[12] Dnipro State Med Univ, Dnipro, Ukraine

[13] Charite Univ Med Berlin, Med Dept Hematol Oncol & Canc Immunol, Berlin, Germany

[14] Servier, Suresnes, France

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 36期

关键词：

bevacizumab; gastrointestinal/colorectal; metastasis; refractory; tipiracil; trifluridine;

D O I：

10.1080/14796694.2024.2366100

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

What is this summary about? This is a summary describing the results from a phase 3 clinical trial called SUNLIGHT. The study looked at treatment with orally administered trifluridine/tipiracil plus intravenously administered bevacizumab in people with metastatic colorectal cancer (mCRC) that is refractory to treatment. This study included people whose cancer had grown or spread beyond its original location after no more than two previous treatments. People in the study received either the combination of trifluridine/tipiracil plus bevacizumab or they received trifluridine/tipiracil alone. The aims of the study were to see how long people lived after treatment with trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil alone and to find out how well the combination of trifluridine/tipiracil plus bevacizumab worked at slowing down the spread of the cancer. Researchers also looked at side effects from taking the medicines and at how treatment affected people's physical functioning. What are the key takeaways? People in the combination group lived longer (a median of 10.8 months) than people who received trifluridine/tipiracil alone (7.5 months). In addition, the time it took for the cancer to worsen was longer for those who received the combination treatment (a median of 5.6 months) compared with those who received trifluridine/tipiracil alone (2.4 months). People's physical functioning took longer to worsen with combination therapy (a median of 9.3 months) than it did with trifluridine/tipiracil alone (6.3 months), as measured by the impact of treatment on people's ability to carry out daily living activities. The most common side effects in both treatment groups were low levels of white blood cells, known as neutrophils (neutropenia), nausea, and low levels of healthy red blood cells (anemia). What were the main conclusions reported by the researchers? The results from the study suggest that treatment with oral trifluridine/tipiracil plus intravenous (IV) bevacizumab could help people with refractory mCRC live longer and maintain good physical functioning, and it could slow the worsening of their cancer.

引用

页码：2823 / 2832

页数：10